[go: up one dir, main page]

WO1993018148A3 - Tumor necrosis factor with modified channel activity - Google Patents

Tumor necrosis factor with modified channel activity Download PDF

Info

Publication number
WO1993018148A3
WO1993018148A3 PCT/US1993/002475 US9302475W WO9318148A3 WO 1993018148 A3 WO1993018148 A3 WO 1993018148A3 US 9302475 W US9302475 W US 9302475W WO 9318148 A3 WO9318148 A3 WO 9318148A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
channel
modified
target
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/002475
Other languages
French (fr)
Other versions
WO1993018148A2 (en
Inventor
Bernadine J Wisnieski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO1993018148A2 publication Critical patent/WO1993018148A2/en
Publication of WO1993018148A3 publication Critical patent/WO1993018148A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

An improved form of tumor necrosis factor (TNF) can be employed to regulate TNF channel activity. The identity of the amino acids which line the channel of the TNF molecule and which exert significant control over the activity of the channel are disclosed. The improved form of TNF includes amino acid substitutions, additions, and/or deletions, and/or chemically modified amino acid residues within the channel region for enhancing, diminishing, and/or modulating its channel activity within target membranes. The modified form of TNF is capable of trimerization and of achieving intimate contact with a target membrane containing one or more types of TNF receptor. Contacting target membranes with forms of TNF having modified channel activities can be employed to regulate the permeability and/or response of the target membrane. Greater control over the regulation of the permeability and/or response of target membranes can be achieved with modified forms of TNF as compared to unmodified TNF.
PCT/US1993/002475 1992-03-12 1993-03-12 Tumor necrosis factor with modified channel activity Ceased WO1993018148A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85262592A 1992-03-12 1992-03-12
US07/852,625 1992-03-12

Publications (2)

Publication Number Publication Date
WO1993018148A2 WO1993018148A2 (en) 1993-09-16
WO1993018148A3 true WO1993018148A3 (en) 1993-10-28

Family

ID=25313824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002475 Ceased WO1993018148A2 (en) 1992-03-12 1993-03-12 Tumor necrosis factor with modified channel activity

Country Status (1)

Country Link
WO (1) WO1993018148A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008290217B2 (en) 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011107991A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Glucocerebrosidase multimers and uses thereof
US9732333B2 (en) 2011-01-20 2017-08-15 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007579A1 (en) * 1988-12-23 1990-07-12 Basf Aktiengesellschaft Tumour necrosis factor muteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007579A1 (en) * 1988-12-23 1990-07-12 Basf Aktiengesellschaft Tumour necrosis factor muteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA vol. 1096, no. 3, 15 April 1991, pages 245 - 252 RYOJI ITO ET AL 'Novel muteins of human Tumor Necrosis Factor-alpha' *
JOURNAL OF BIOCHEMISTRY. vol. 102, no. 5, 1987, TOKYO JP pages 1303 - 1310 N. OKU ET AL 'Tumor Necrosis Factor-induced permeability increase of negatively charged phospholipid vesicles' *
JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 264, no. 29, 15 October 1989, BALTIMORE US pages 17595 - 17605 M. J. ECK ET AL 'the structure of Tumor Necrosis Factor-alpha at 2.6 A resolution' *
JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 267, no. 4, 5 February 1992, BALTIMORE US pages 2119 - 2122 M. J. ECK ET AL 'The structure of human Lymphotoxin (Tumor Necrosis Factor-beta) at 1.9-A resolution' cited in the application *
JOURNAL OF IMMUNOLOGY. vol. 141, no. 7, 1 October 1988, BALTIMORE US pages 2352 - 2357 R. L. BALDWIN ET AL 'Capacity of Tumor Necrosis Factor to bind and penetrate menbranes is pH-dependent' *
SCIENCE vol. 255, 13 March 1992, LANCASTER, PA US pages 1427 - 1430 B. L. KAGAN ET AL 'formation of ion-permeable channels by tumor necrosis factor -alpha' cited in the application *

Also Published As

Publication number Publication date
WO1993018148A2 (en) 1993-09-16

Similar Documents

Publication Publication Date Title
Lumsden et al. The subunit structure of the arom multienzyme complex of Neurospora crassa. A possible pentafunctional polypeptide chain
WO1994003616A3 (en) Cloning and/or sequencing vector
ATE73856T1 (en) PURIFICATION, PREPARATION AND USE OF TUMOR NECROSIS FACTORS.
YU299A (en) Truncated soluble tumor necrosis factor type-i and type-ii
DK45190A (en) METHOD OF PREPARING GLUCOSE OXIDASE
CA2247860A1 (en) Method for treating liquid materials
EP0489711A3 (en) Method for producing human growth hormone
EP0718400A3 (en) Methods and compositions for controlling translation of HCV proteins
AU6123086A (en) Chromatographic recovery of erythropoietin
WO1993018148A3 (en) Tumor necrosis factor with modified channel activity
ATE119543T1 (en) PRODUCTION OF PROTEINS IN ACTIVE FORM.
AU577810B2 (en) Cloning the gene for rabbit tumor necrosis factor polypeptide
ES8506804A1 (en) A PROCEDURE FOR PRODUCING L-ARGININ
DE58908428D1 (en) Secretary mutant of Escherichia coli.
Himeno et al. The Synthesis of Rat Liver Lysosomes: III. Chemical Composition of Microsomal and Lysosomal β-Glucuronidases Purified from Rat Liver
DK267386A (en) MASSIVE WOOD IMPROVEMENT AGENT AND PRESSURE PRIMATING PROCEDURE
EP1331265A3 (en) density enhanced protein tyrosine phosphatases
EP0336383A3 (en) Novel recombinant human lymphotoxin
DK0938501T3 (en) Process for Purification of Recombinant E. Coli Human Interleukin-1 Receptor Antagonist
DK460784D0 (en) PROCEDURE FOR RACEMIZING OPTICALLY ACTIVE AMINO ACIDS
KR910004811A (en) Optimal Fermentation Method for Producing Heterologous Proteins in E. coli
Paberit et al. Isolation and properties of neutral metalloprotease from thermophilic bacteria Bacillus brevis.
EP0302459A3 (en) Human placenta-derived thermostable cell growth factor and a process for production thereof
KONAMI et al. Purification and Characterization of a Cytisus-type Ulex europeus Hemagglutinin II by Affinity Chromatography
AU5652286A (en) Media for increased yield of protein free of N-terminal methionine from recombinant escherichia coli

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA